Global Biologics Contract Development and Manufacturing Organization (CDMO) Market, Forecast to 2022
Investments in Single Use/Disposable Technologies to Capitalize on Growth Opportunities in High-value Low-volume Biologics
  • The global pharmaceutical industry is evolving with the rising need for novel therapies in the changing disease landscape. As a result of rising prevalence of chronic infectious diseases as well as growing cancer incidence, market needs are shifting from traditional small molecules to large molecules. This study presents an overview of the global biologics Contract Development and Manufacturing Organization (CDMO) landscape with an emphasis on the key trends and growth opportunities across the global biologics outsourcing market. It also highlights the shifting focus and investments of pharma/biotech participants toward BioCDMOs for innovative biologics discovery, development, and manufacturing.

    • Get Access to Complimentary Intelligence
    • * indicates mandatory fields
    • Firstname*
    • Lastname*
    • Company*
    • Job Title*
    • Business Phone*
    • Job Role*
    • Business Email*
    • Industry
    • Are you in the media?*
    • We'd love to send you exclusive offers and the latest info from Frost & Sullivan in the areas of:
    • Please tick the boxes below to tell us all the ways you would prefer to hear from us:
    • Frost & Sullivan values your privacy and we will never share or sell your personal information to third parties. Please visit our Privacy Policy.